BRPI0411944A - specific human antibodies - Google Patents

specific human antibodies

Info

Publication number
BRPI0411944A
BRPI0411944A BRPI0411944-4A BRPI0411944A BRPI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A
Authority
BR
Brazil
Prior art keywords
present
antibodies
antibody
administering
agent
Prior art date
Application number
BRPI0411944-4A
Other languages
Portuguese (pt)
Inventor
Daniel Plaksin
Avigdor Levanon
Esther Szanton
Yocheved Hagay
Rachel Ben-Levy
Yariv Kanfi
Tikva Vogel
Tuvia Peretz
Lena Cooperman
Boaz Amit
Tall Szrajber
Original Assignee
Bio Technology General Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Israel filed Critical Bio Technology General Israel
Publication of BRPI0411944A publication Critical patent/BRPI0411944A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

"ANTICORPOS HUMANOS ESPECìFICOS". A presente invenção fornece anticorpos que se ligam a um epitopo do PSGL-1 que consiste no motivo D-X-Y-D, em que X representa qualquer aminoácido ou a ligação co-valente entre D e Y, e Y é sulfatado, o anticorpo pode ser complexado com uma ou mais cópias de um agente. Os anticorpos da invenção podem ser usados em um método de indução de citotoxicidade de célula dependente de anticorpo e/ou estímulo de células assassinas naturais (NK) ou células T. Além disso, administrando esses anticorpos a um paciente necessitado, é fornecido um método de indução à morte da célula. Também é fornecido um método de prevenção de infecção por um vírus (por ex., HIV), administrando a um paciente um anticorpo da presente invenção. A presente invenção também fornece um método de introdução de um agente em uma célula que expresse PSGL-1 sulfatado, unindo ou complexando um agente a um anticorpo da presente invenção e administrando o complexo à célula. Por fim, a presente invenção fornece métodos de diagnósticos, prognóstico e estadiamento usando os anticorpos presentes."SPECIFIC HUMAN ANTIBODIES". The present invention provides antibodies that bind to a PSGL-1 epitope consisting of the DXYD motif, where X represents any amino acid or the co-valent bond between D and Y, and Y is sulfated, the antibody may be complexed with a or more copies of an agent. The antibodies of the invention may be used in a method of inducing antibody-dependent cell cytotoxicity and / or stimulating natural killer cells (NK) or T cells. In addition, by administering such antibodies to a patient in need, a method of induction of cell death. Also provided is a method of preventing infection by a virus (e.g., HIV) by administering to a patient an antibody of the present invention. The present invention also provides a method of introducing an agent into a sulfated PSGL-1 expressing cell by attaching or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides diagnostic, prognostic and staging methods using the present antibodies.

BRPI0411944-4A 2003-06-30 2004-06-30 specific human antibodies BRPI0411944A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61084003A 2003-06-30 2003-06-30
PCT/US2004/021099 WO2005005455A2 (en) 2003-06-30 2004-06-30 Specific human antibodies

Publications (1)

Publication Number Publication Date
BRPI0411944A true BRPI0411944A (en) 2007-01-02

Family

ID=34062326

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411944-4A BRPI0411944A (en) 2003-06-30 2004-06-30 specific human antibodies

Country Status (11)

Country Link
EP (1) EP1646401A4 (en)
JP (1) JP2007527393A (en)
KR (1) KR20060107501A (en)
CN (1) CN1897970A (en)
AU (1) AU2004256113A1 (en)
BR (1) BRPI0411944A (en)
CA (1) CA2531283A1 (en)
IL (1) IL172511A0 (en)
MX (1) MXPA06000253A (en)
RU (1) RU2006102571A (en)
WO (1) WO2005005455A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
FR2894983B1 (en) * 2005-12-16 2012-08-17 Lab Francais Du Fractionnement ANTIBODY CHARACTERIZATION TEST.
BRPI0817099A2 (en) * 2007-09-13 2015-03-24 Delenex Therapeutics Ag An isolated antibody that selectively binds to beta-amyloid peptide, a pharmaceutical composition comprising said antibody, nucleic acid sequence, vector and host cell
US8742076B2 (en) 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
BRPI0910810A2 (en) * 2008-07-15 2019-09-24 Genentech Inc anthracycline derivative conjugates, polymeric carrier, antibody, peptide or protein, t- [cho] m carrier, pharmaceutical compositions, methods of treating cancer or cell proliferation disorders, anthracycline derivative, drug-antibody conjugate compound, use, article of Manufacture and Method of Production of a Drug-Antibody Conjugate Compound "
WO2012174001A1 (en) 2011-06-13 2012-12-20 Abgenomics Cooperatief U.A. Anti-psgl-1 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
WO2001064710A2 (en) * 2000-02-29 2001-09-07 Progenics Pharmaceuticals, Inc. Sulfated ccr5 peptides for hiv-1 infection
EP1406930A4 (en) * 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
NZ527173A (en) * 2000-12-29 2006-03-31 Savient Pharmaceuticals Inc Specific human antibodies for selective cancer therapy

Also Published As

Publication number Publication date
IL172511A0 (en) 2006-04-10
JP2007527393A (en) 2007-09-27
MXPA06000253A (en) 2007-03-08
KR20060107501A (en) 2006-10-13
EP1646401A2 (en) 2006-04-19
AU2004256113A1 (en) 2005-01-20
RU2006102571A (en) 2007-08-20
EP1646401A4 (en) 2007-07-18
WO2005005455A3 (en) 2006-02-16
WO2005005455A2 (en) 2005-01-20
CA2531283A1 (en) 2005-01-20
CN1897970A (en) 2007-01-17

Similar Documents

Publication Publication Date Title
Ofek et al. Adherence of Escherichia coli to human mucosal cells mediated by mannose receptors
Reid et al. Pathology illustrated E-book
BR0313336A (en) Pacifier for use in a user's mouth
Hecht et al. Predominance of hemoglobin Gower 1 in early human embryonic development
HUP0300951A2 (en) Ethylenedicysteine(ec)-drug conjugates, preparations and methods for tissue-specific disease imaging
DK1053256T3 (en) Antibodies to Death Receptor 4 (DR4) and Applications thereof
Cahan et al. Sialyloligosaccharide receptors of binding variants of polyoma virus
BRPI0411944A (en) specific human antibodies
Pallavi et al. Hepatitis-A: Review on Current and Future Scenario
DE69841322D1 (en) HEPATITIS C RECEPTOR PROTEIN CD81
Michel Self-cure in infections of Trichostrongylus retortaeformis and its causation
Lesnicar A prospective study of viral hepatitis A and the question of chronicity
Raffel Bacterial hypersensitivity
BR9612422A (en) Recombinant viral pseudo-particles, composition, use of pseudo-particles, and process of in vitro stimulation of cytotoxic t responses of lymphocytes from individuals affected by viral or tumor infections.
Bernard et al. NK Cells in Protection from HIV Infection
BR0210486A (en) Protein, recombinant polypeptide, nucleic acid sequence and vector, cultured cell, nucleotide primer, purified antibody, immunogenic, vaccine and pharmaceutical compositions, screening process for molecules likely to inhibit growth of major leishmania, use of an acid probe nucleic acid, one or more inhibitors of protein disulfide isomerases and bacitracin or zinc bacitracin, in vitro diagnostic method of a parasitic infection responsible for leishmaniasis and diagnostic kit for carrying out the method
Pande et al. A case report of Plasmodium vivax, Plasmodium falciparum and dengue co-infection in a 6 months pregnancy
ATE249227T1 (en) USE OF FUCOSILATED SIALILATED N-ACETYL-LACTOSAMINE CARBOHYDRATE STRUCTURES TO INHIBIT BACTERIAL ADHESION
Stone et al. Case 10-2013: a 30-year-old man with fever, myalgias, arthritis, and rash
Ogidi et al. Covid-19 vaccination: the pros and cons
Violand et al. Permeabilization of Ehrlich ascites tumor cells by human serum
Tibenderana Outbreak of Marburg Virus in northwest Tanzania: Unleashing health emergency
Kawiak et al. Cytochemical characterization of mouse L1210 leukemia
Martin et al. History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications
Warren et al. PR 879-317A enhances in vitro immune activity of peripheral blood mononuclear cells from patients with Down syndrome

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.